居里 CRIS 深 沪
等待开盘 08-14 09:30:00 美东时间
1.87
+0.200
+11.98%
华盛通- 最 高2.08
- 今 开1.58
- 成交量 229.27万股
- 最 低 1.54
- 昨 收 1.67
- 总市值 364.45万
- 52周最高 39.00
- 市盈率 静 --
- 换手率 117.64%
- 52周最低 1.54
- 委 比 -50.00%
- 总股本 194.89万
- 历史最高 11300.00
- 量 比 5.82
- 振 幅 32.34%
- 历史最低 1.54
- 每 手 1
- 风险率 9.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Curis prices $5.6 million public offering
Curis (CRIS) announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3.73M shares of common stock of the comp...
08-13 20:40
Curis, Inc. Announces Pricing of $5.6 Million Public Offering
LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule I...
08-13 20:00
Curis Regains Nasdaq Compliance, Faces One-Year Monitoring
Curis ( ($CRIS) ) has shared an update. On July 24, 2026, Curis, Inc. received ...
07-31 05:20
Curis Doses First Five Patients in TakeAim CLL Study
LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule I...
07-30 20:00
美股大行评级 | 最高120美元！大小摩等7家大行集体上调英特尔目标价；汇丰首予SpaceX"持有"评级，目标价115美元
今日重点评级关注：HC Wainwright & Co.：维持居里"买入"评级，目标价从17美元升至43美元；花旗：维持Klaviyo"买入"评级，目标价从31美元升至34美元
07-27 14:02
新股前瞻|核药产业爆发前夜，蓝纳成能否成为千亿赛道先行者？
此番东诚药业推动蓝纳成分拆赴港上市，既助力了这家尚处于研发投入期的子公司拓宽融资渠道、加速管线推进，也为港股投资者提供了分享核药赛道发展红利的难得机遇。
07-25 13:55
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus
On Wednesday, Curis Inc. (NASDAQ:CRIS) announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance. The biotechnology firm detailed key advances across its ongoing clinical programs evaluating the oral IRAK4 and FLT3 inhibito...
07-25 02:03
HC Wainwright & Co. Maintains Buy on Curis, Raises Price Target to $43
HC Wainwright & Co. analyst Sara Nik maintains Curis (NASDAQ:CRIS) with a Buy and raises the price target from $17 to $43.
07-24 18:14
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates
Curis Inc. (NASDAQ:CRIS) on Wednesday announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance. The biotechnology firm detailed key advances across its ongoing clinical programs evaluating the oral IRAK4 and FLT3 inhibitor...
07-23 01:04
